Dataset Information

Validation of EGFL6 expression as a prognostic marker in patients with lung adenocarcinoma in Taiwan: a retrospective study.

ABSTRACT:

Objective

Lung adenocarcinoma is a non-small cell lung cancer, a common cancer in both genders, and has poor clinical outcome. Our aim was to evaluate the role of epidermal growth factor (EGF)-like domain multiple 6 (EGFL6) and its prognostic significance in lung adenocarcinoma.

Methods

EGFL6 expression was studied by immunohistochemical staining of specimens from 150 patients with lung adenocarcinoma. The correlation between clinicopathological features and EGFL6 expression was quantitatively analysed. We used Kaplan-Meier analysis and Cox proportional hazard models to examine the prognostic value of EGFL6 in terms of overall survival.

Results

No significant correlation was found between EGFL6 expression and clinical parameters. However, patients with high levels of EGFL6 expression showed a tendency towards poor prognosis, with borderline statistical significance. Grouping the patients according to a medium age value revealed a significant association between high EGFL6 expression and poor clinical outcome in young patients. This finding was further confirmed by grouping the patients into three groups according to age. HR in patients with high EGFL6 expression was higher in younger patients than in older patients.

Conclusion

High EGFL6 expression may serve as a marker for poor prognosis of lung adenocarcinoma, especially in younger patients.

SUBMITTER: Chang CC

PROVIDER: S-EPMC6020984 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Validation of EGFL6 expression as a prognostic marker in patients with lung adenocarcinoma in Taiwan: a retrospective study.

Chang Chun-Chi CC Sung Wen-Wei WW Hsu Hui-Ting HT Yeh Chung-Min CM Lee Chien-Hsun CH Chen Ya-Ling YL Liu Ta-Chih TC Yeh Kun-Tu KT

BMJ open 20180622 6

<h4>Objective</h4>Lung adenocarcinoma is a non-small cell lung cancer, a common cancer in both genders, and has poor clinical outcome. Our aim was to evaluate the role of epidermal growth factor (EGF)-like domain multiple 6 (EGFL6) and its prognostic significance in lung adenocarcinoma.<h4>Methods</h4>EGFL6 expression was studied by immunohistochemical staining of specimens from 150 patients with lung adenocarcinoma. The correlation between clinicopathological features and EGFL6 expression was q ...[more]

PMID: 29934389

Similar Datasets

Project description:BackgroundCuproptosis induction is seen as a promising alternative for immunotherapies and targeted therapies in breast cancer. The objective of this research was to examine the prognostic and biological importance of cuproptosis-related genes (CRGs) in lung adenocarcinoma (LUAD).MethodsThe following methods were used: GSE10072 dataset and TCGA database analysis, differential expression analysis of CRGs, and biological function (BP) and signaling pathway enrichment analysis, prognostic analysis and clinical analysis of CRGs, construction of the prognostic signature and RNA modified genes and miRNA analysis of CRGs in LUAD, immunoinfiltration analysis and immunohistochemical staining of DβH, UBE2D3, SOD1, UBE2D1 and LOXL2.ResultsAOC1, ATOX1, CCL8, CCS, COX11, CP, LOXL2, MAP2K2, PDK1, SCO2, SOD1, UBE2D1, UBE2D3 and VEGFA showed significantly higher expression, while ATP7B, DβH, PDE3B, SLC31A2, UBE2D2, UBE2D4 and ULK2 showed lower expression in LUAD tissues than normal tissues. We also found that ATP7B (4%), AOC1 (3%) PDE3B (2%), DβH (2%), CP (1%), ULK2 (1%), PDK1 (1%), LOXL2 (1%) and UBE2D3 (1%) showed higher mutation frequencies. The univariate Cox analysis was used to identify CRGs that have prognostic value. It identified 21 genes that showed significant prognostic value, containing DβH, UBE2D3, SOD1, UBE2D1 and LOXL2. Patients with DβH up-expression have a longer survival time and patients with UBE2D3, SOD1, UBE2D1 and LOXL2 down-expression also have a longer survival time. hsa-miR-29c-3p, hsa-miR-29a-3p, hsa-miR-181c-5p, hsa-miR-1245a, etc., play an important role in the miRNA regulatory network, and in LUAD, miR-29a, miR-29c and miR-181c high expression survival was longer, and miR-1245a low expression survival was longer. We also performed an analysis to examine the relationships between DβH, LOXL2, SOD1, UBE2D1 and UBE2D3 and immune infiltration in LUAD, including B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils and DCs.ConclusionDβH, UBE2D3, SOD1, UBE2D1, and LOXL2 are potential candidates implicated in LUAD and can be further explored for their application as diagnostic, prognostic, and therapeutic biomarkers for LUAD.

Project description:BackgroundLung adenocarcinoma (LUAD) is the predominant histological subtype of lung cancer. In the past decade, various targeted drugs have prolonged the survival of LUAD patients. Unfortunately, not all LUAD patients can benefit from the current target agents. Although the membrane spanning 4-domains A15 (MS4A15) gene has been implicated in the progression of various cancers, its role in LUAD remains understudied. This study aimed to evaluate the role and potential mechanism of MS4A15 in the progression of LUAD.MethodsThe pan-cancer RNA sequencing and clinical data of LUAD patients, originally comprising data from The Cancer Genome Atlas and Genotypic Tissue Expression, were acquired from University of California Santa Cruz XENA (UCSC XENA). Additionally, the GSE116959 and GSE130779 data sets were retrieved from the Gene Expression Omnibus database. The Differential Expression analysis of Sequencing data version 2 (DESeq2) package was used to identify the differentially expressed genes. The ClusteProfiler package was used to perform the Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and gene set enrichment analyses. An immune cell infiltration analysis was conducted using the gene set variation analysis (GSVA) package. The expression level of MS4A15 was analyzed by the Wilcoxon rank-sum test. A logistic regression analysis was conducted to examine the correlation between the clinical pathological factors of LUAD patients and the high-low dichotomy of MS4A15. A receiver operating characteristic (ROC) curve analysis was employed to evaluate the effectiveness of MS4A15 as a biomarker for distinguishing LUAD patients from healthy individuals. A Kaplan-Meier analysis was conducted to examine the overall survival of LUAD patients based on MS4A15. All the bioinformatic results were obtained using R (version 3.6.2) package. Real-time quantitative polymerase chain reaction (RT-qPCR) was performed to validate the messenger RNA transcription level in vitro.ResultsMS4A15 expression was significantly more decreased in the tumor tissues from the LUAD patients than the normal adjacent samples. MS4A15 expression was positively correlated with various immune cell types, notably including mast cells (MCs), dendritic cells, and macrophages. Specifically, MS4A15 was most positively associated with MCs. Lower expression levels of MS4A15 in LUAD patients were correlated with a poorer pathologic stage and poorer primary therapy outcomes. The area under the curve of the ROC curve for MS4A15 effectiveness was 0.863. MS4A15 was validated to be more lowly expressed in the tumor tissues samples than the normal tissues samples in both the GSE116959 and GSE130779 data sets. The expression of MS4A15 was also significantly lower in the in A549 cells than the normal human bronchial epithelia cells.ConclusionsOverall, MS4A15 emerged as a promising prognostic biomarker for LUAD and could serve as a potential target for the development of novel therapeutic interventions.

Dataset Information

Validation of EGFL6 expression as a prognostic marker in patients with lung adenocarcinoma in Taiwan: a retrospective study.

Objective

Methods

Results

Conclusion

Publications

Validation of EGFL6 expression as a prognostic marker in patients with lung adenocarcinoma in Taiwan: a retrospective study.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets